Wednesday 6-18-2014 Arena Pharmaceuticals (ARNA) $
Post# of 71
Posted On: 06/18/2014 8:53:19 PM
Wednesday 6-18-2014 Arena Pharmaceuticals (ARNA) $ARNA opened at 6.19 hitting the high price of 6.24 and a day low of 6.12 with a total volume of 3,788,199. ARNA had a previous close of 6.20 and has been seeing an average volume of 4,325,485.
Overall Average: 32% Sell
Recent stock forum discussions about ARNA http://investorshangout.com/search?q=ARNA&...mp;yt0=Go!
Is It Time to Buy Orexigen?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Fri Jun 13, 10:12PM CDT
Orexigen 's news this week wasn't all bad -- after all, it looks like drug Contrave is a good bet for approval, the market's unhappiness about the FDA's delayed PDUFA date notwithstanding. The delay in potential approval was tied to the need to... (full story)
Arena Pharmaceuticals to Present at the 2014 Wells Fargo Securities Healthcare Conference
PR Newswire - Fri Jun 13, 7:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the 2014 Wells Fargo Securities Healthcare Conference on Wednesday, June 18, 2014, at 2:25 p.m. Eastern Time (11:25 a.m. Pacific Time), at the InterContinental Hotel in Boston, Massachusetts. (full story)
Today's Top Biotech Stocks to Watch: Geron Corporation and Arena Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Thu Jun 12, 7:26AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Geron Corporation and Arena Pharmaceuticals . Shares of clinical-stage biotech Geron are up over 30% in premarket this morning after the company... (full story)
EnteroMedics: A Preview of the Weight-Loss Zapper FDA Panel
at The Street - Thu Jun 12, 7:00AM CDT
EnteroMedics and its VBLOC "fat-zapping" implantable medical device will be the focus of an FDA advisory panel meeting next Tuesday, June 17. If FDA follows historical form, the agency's review of VBLOC's safety and efficacy will be available... (full story)
'Fast Money' Recap: Reacting to Today's Headlines
at The Street - Thu Jun 12, 4:00AM CDT
The trading panel discussed whether a market pullback is in the card anytime soon. (full story)
FDA delays Orexigen drug
at Investor's Business Daily - Wed Jun 11, 5:57PM CDT
The agency delayed a decision on Orexigen's (OREX) obesity drug NB32, also known as Contrave, by 3 months. The FDA didn't accept the drug in '11 over concerns about cardiovascular risk. The news is a blow to the weight-loss drug industry. Obesity... (full story)
Why Orexigen Therapeutics Inc. Shares Were Throttled
Sean Williams, The Motley Fool - Motley Fool - Wed Jun 11, 2:35PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Orexigen Therapeutics , a clinical-stage... (full story)
Why Orexigen Therapeutics is Falling Today
George Budwell, The Motley Fool - Motley Fool - Wed Jun 11, 1:09PM CDT
Shares of Orexigen Therapeutics fell more than 15% this morning on heavy volume after the company announced that the Food and Drug Administration had pushed back its review of the company's resubmitted new drug application for Contrave. As a... (full story)
Orexigen falls on further FDA delays for diet pill
By The Associated Press - AP - Wed Jun 11, 11:58AM CDT
Shares of Orexigen Therapeutics tumbled more than 16 percent in afternoon trading Wednesday after regulators extended by three months a review of its experimental weight loss treatment. (full story)
Orexigen Obesity Drug Decision Delayed By FDA
at Investor's Business Daily - Wed Jun 11, 10:55AM CDT
The obesity-drug business received another blow Wednesday when the FDA delayed a decision on Orexigen's (OREX) NB32, also known as Contrave, by three months. Orexigen's stock plunged 18% to below 6 in morning trading on the stock market. In a press... (full story)
Down 18%: Is Orexigen a Bad News Buy?
Michael Douglass and Jason Moser, The Motley Fool - Motley Fool - Wed Jun 11, 10:33AM CDT
Orexigen Therapeutics (NASDAQ: OREX) reported this morning that the FDA is delaying a decision on its anti-obesity drug Contrave for three months -- until September 11th. The stock promptly sold off (down 18% as of this writing) as investors reacted... (full story)
FDA Delays Decision on Orexigen Obesity Pill by 3 Months
at The Street - Wed Jun 11, 5:48AM CDT
FDA needs more time to reach agreement on the post-marketing obligation related to the previously agreed upon evaluation of heart-safety related outcomes for Contrave, Orexigen said (full story)
Orexigen's Date With Destiny
Brian Orelli, The Motley Fool - Motley Fool - Tue Jun 10, 2:08PM CDT
This week, Orexigen 's obesity drug, Contrave, is up for Food and Drug Administration approval. Again. The biotech originally tried to gain approval for Contrave a few years ago, but the FDA rejected the drug, asking for a clinical trial to... (full story)
Dosing Initiation, Conferences Participation, Trial Results Publication, and Financial Results - Analyst Notes on Arena, Acceleron Pharma, HealthSouth, The Medicines Company and Taro
PR Newswire - Tue Jun 10, 4:40AM CDT
Today, Analysts Review released its analysts' notes regarding Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Acceleron Pharma Inc. (NASDAQ: XLRN), HealthSouth Corporation (NYSE: HLS), The Medicines Company (NASDAQ: MDCO) and Taro Pharmaceutical Industries Ltd. (NYSE: TARO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3548-100free. (full story)
Pulmonary Arterial Hypertension - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pfk67l/pulmonary) has announced the addition of the "Pulmonary Arterial Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Arterial Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - United Therapeutics Corporation - Merck & Co., Inc. - Novartis AG - Actelion Ltd - Nippon Shinyaku Co., Ltd. - Toray Industries, Inc. - Celladon Corporation - Arena Pharmaceuticals, Inc. - Cytokinetics, Incorporated - HanAll Biopharma Co., Ltd. - Pluristem Therapeutics Inc. - Proteo, Inc. - Ironwood Pharmaceuticals, Inc. - Aires Pharmaceuticals, Inc. - Cardioxyl Pharmaceuticals, Inc. - Therametrics holding AG - PhaseBio Pharmaceuticals, Inc. - Asahi Kasei Pharma Corp. - Reata Pharmaceuticals, Inc. - Polyphor Ltd. - Lacer, S.A. - Ikaria Inc. - Bial - Portela & Ca, S.A. - Northern Therapeutics, Inc. - miRagen Therapeutics, Inc. - PharmaIN Corporation - Tarix Pharmaceuticals LTD. - EGEN, Inc. - Corridor Pharmaceuticals Inc. - Sagene Pharmaceuticals, Inc. - Mezzion Pharma Co. Ltd. - Sinoxa Pharma GmbH For more information visit http://www.researchandmarkets.com/research/pfk67l/pulmonary (full story)
Does Wall Street Still Hate Arena Pharmaceuticals?
George Budwell, The Motley Fool - Motley Fool - Mon Jun 09, 5:00PM CDT
It's no secret that Wall Street has been betting heavily against Arena Pharmaceuticals , both before and after the Food and Drug Administration approved the company's fat-fighting pill, Belviq. The investing thesis is simple and to the point:... (full story)
As Orexigen Faces FDA Will Weight Loss Landscape Change?
Alexander Maxwell, The Motley Fool - Motley Fool - Mon Jun 09, 1:05PM CDT
As Orexigen Pharmaceuticals once again prepares to face the FDA over its weight loss drug Contrave, we must take a look at how this may change the landscape for the weight loss drug market. Adding another competitor is not necessarily good news... (full story)
Orexigen: 'Goldilocks' Obesity Pill Awaits FDA Approval Decision Wednesday
at The Street - Mon Jun 09, 11:43AM CDT
Selling weight-loss pills to fat Americans is clearly more difficult than Vivus and Arena envisioned. Orexigen will face the same challenges, but of the three companies, it has the best marketing partner in Takeda because of its metabolic drug... (full story)
Lorcaserin HCl Data to be Presented at American Diabetes Association's 74th Scientific Sessions
PR Newswire - Mon Jun 09, 6:55AM CDT
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ® (lorcaserin HCl) CIV will be presented at the American Diabetes Association's (ADA) 74th Scientific Sessions taking place June 13-17, 2014 in San Francisco, California. (full story)
Biotech Stock Hate Mailbag: The Hostile React-o-Meter Meltdown Edition
at The Street - Fri Jun 06, 9:32AM CDT
I've been getting so much hate mail and nasty tweets lately, I thought it would be fun to throw them all into a single column for funny Friday read. There's probably something deeper to be said about market psychology and what an uptick in hate mail... (full story)
Overall Average: 32% Sell
Recent stock forum discussions about ARNA http://investorshangout.com/search?q=ARNA&...mp;yt0=Go!
Is It Time to Buy Orexigen?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Fri Jun 13, 10:12PM CDT
Orexigen 's news this week wasn't all bad -- after all, it looks like drug Contrave is a good bet for approval, the market's unhappiness about the FDA's delayed PDUFA date notwithstanding. The delay in potential approval was tied to the need to... (full story)
Arena Pharmaceuticals to Present at the 2014 Wells Fargo Securities Healthcare Conference
PR Newswire - Fri Jun 13, 7:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the 2014 Wells Fargo Securities Healthcare Conference on Wednesday, June 18, 2014, at 2:25 p.m. Eastern Time (11:25 a.m. Pacific Time), at the InterContinental Hotel in Boston, Massachusetts. (full story)
Today's Top Biotech Stocks to Watch: Geron Corporation and Arena Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Thu Jun 12, 7:26AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Geron Corporation and Arena Pharmaceuticals . Shares of clinical-stage biotech Geron are up over 30% in premarket this morning after the company... (full story)
EnteroMedics: A Preview of the Weight-Loss Zapper FDA Panel
at The Street - Thu Jun 12, 7:00AM CDT
EnteroMedics and its VBLOC "fat-zapping" implantable medical device will be the focus of an FDA advisory panel meeting next Tuesday, June 17. If FDA follows historical form, the agency's review of VBLOC's safety and efficacy will be available... (full story)
'Fast Money' Recap: Reacting to Today's Headlines
at The Street - Thu Jun 12, 4:00AM CDT
The trading panel discussed whether a market pullback is in the card anytime soon. (full story)
FDA delays Orexigen drug
at Investor's Business Daily - Wed Jun 11, 5:57PM CDT
The agency delayed a decision on Orexigen's (OREX) obesity drug NB32, also known as Contrave, by 3 months. The FDA didn't accept the drug in '11 over concerns about cardiovascular risk. The news is a blow to the weight-loss drug industry. Obesity... (full story)
Why Orexigen Therapeutics Inc. Shares Were Throttled
Sean Williams, The Motley Fool - Motley Fool - Wed Jun 11, 2:35PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Orexigen Therapeutics , a clinical-stage... (full story)
Why Orexigen Therapeutics is Falling Today
George Budwell, The Motley Fool - Motley Fool - Wed Jun 11, 1:09PM CDT
Shares of Orexigen Therapeutics fell more than 15% this morning on heavy volume after the company announced that the Food and Drug Administration had pushed back its review of the company's resubmitted new drug application for Contrave. As a... (full story)
Orexigen falls on further FDA delays for diet pill
By The Associated Press - AP - Wed Jun 11, 11:58AM CDT
Shares of Orexigen Therapeutics tumbled more than 16 percent in afternoon trading Wednesday after regulators extended by three months a review of its experimental weight loss treatment. (full story)
Orexigen Obesity Drug Decision Delayed By FDA
at Investor's Business Daily - Wed Jun 11, 10:55AM CDT
The obesity-drug business received another blow Wednesday when the FDA delayed a decision on Orexigen's (OREX) NB32, also known as Contrave, by three months. Orexigen's stock plunged 18% to below 6 in morning trading on the stock market. In a press... (full story)
Down 18%: Is Orexigen a Bad News Buy?
Michael Douglass and Jason Moser, The Motley Fool - Motley Fool - Wed Jun 11, 10:33AM CDT
Orexigen Therapeutics (NASDAQ: OREX) reported this morning that the FDA is delaying a decision on its anti-obesity drug Contrave for three months -- until September 11th. The stock promptly sold off (down 18% as of this writing) as investors reacted... (full story)
FDA Delays Decision on Orexigen Obesity Pill by 3 Months
at The Street - Wed Jun 11, 5:48AM CDT
FDA needs more time to reach agreement on the post-marketing obligation related to the previously agreed upon evaluation of heart-safety related outcomes for Contrave, Orexigen said (full story)
Orexigen's Date With Destiny
Brian Orelli, The Motley Fool - Motley Fool - Tue Jun 10, 2:08PM CDT
This week, Orexigen 's obesity drug, Contrave, is up for Food and Drug Administration approval. Again. The biotech originally tried to gain approval for Contrave a few years ago, but the FDA rejected the drug, asking for a clinical trial to... (full story)
Dosing Initiation, Conferences Participation, Trial Results Publication, and Financial Results - Analyst Notes on Arena, Acceleron Pharma, HealthSouth, The Medicines Company and Taro
PR Newswire - Tue Jun 10, 4:40AM CDT
Today, Analysts Review released its analysts' notes regarding Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Acceleron Pharma Inc. (NASDAQ: XLRN), HealthSouth Corporation (NYSE: HLS), The Medicines Company (NASDAQ: MDCO) and Taro Pharmaceutical Industries Ltd. (NYSE: TARO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3548-100free. (full story)
Pulmonary Arterial Hypertension - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pfk67l/pulmonary) has announced the addition of the "Pulmonary Arterial Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Arterial Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - United Therapeutics Corporation - Merck & Co., Inc. - Novartis AG - Actelion Ltd - Nippon Shinyaku Co., Ltd. - Toray Industries, Inc. - Celladon Corporation - Arena Pharmaceuticals, Inc. - Cytokinetics, Incorporated - HanAll Biopharma Co., Ltd. - Pluristem Therapeutics Inc. - Proteo, Inc. - Ironwood Pharmaceuticals, Inc. - Aires Pharmaceuticals, Inc. - Cardioxyl Pharmaceuticals, Inc. - Therametrics holding AG - PhaseBio Pharmaceuticals, Inc. - Asahi Kasei Pharma Corp. - Reata Pharmaceuticals, Inc. - Polyphor Ltd. - Lacer, S.A. - Ikaria Inc. - Bial - Portela & Ca, S.A. - Northern Therapeutics, Inc. - miRagen Therapeutics, Inc. - PharmaIN Corporation - Tarix Pharmaceuticals LTD. - EGEN, Inc. - Corridor Pharmaceuticals Inc. - Sagene Pharmaceuticals, Inc. - Mezzion Pharma Co. Ltd. - Sinoxa Pharma GmbH For more information visit http://www.researchandmarkets.com/research/pfk67l/pulmonary (full story)
Does Wall Street Still Hate Arena Pharmaceuticals?
George Budwell, The Motley Fool - Motley Fool - Mon Jun 09, 5:00PM CDT
It's no secret that Wall Street has been betting heavily against Arena Pharmaceuticals , both before and after the Food and Drug Administration approved the company's fat-fighting pill, Belviq. The investing thesis is simple and to the point:... (full story)
As Orexigen Faces FDA Will Weight Loss Landscape Change?
Alexander Maxwell, The Motley Fool - Motley Fool - Mon Jun 09, 1:05PM CDT
As Orexigen Pharmaceuticals once again prepares to face the FDA over its weight loss drug Contrave, we must take a look at how this may change the landscape for the weight loss drug market. Adding another competitor is not necessarily good news... (full story)
Orexigen: 'Goldilocks' Obesity Pill Awaits FDA Approval Decision Wednesday
at The Street - Mon Jun 09, 11:43AM CDT
Selling weight-loss pills to fat Americans is clearly more difficult than Vivus and Arena envisioned. Orexigen will face the same challenges, but of the three companies, it has the best marketing partner in Takeda because of its metabolic drug... (full story)
Lorcaserin HCl Data to be Presented at American Diabetes Association's 74th Scientific Sessions
PR Newswire - Mon Jun 09, 6:55AM CDT
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ® (lorcaserin HCl) CIV will be presented at the American Diabetes Association's (ADA) 74th Scientific Sessions taking place June 13-17, 2014 in San Francisco, California. (full story)
Biotech Stock Hate Mailbag: The Hostile React-o-Meter Meltdown Edition
at The Street - Fri Jun 06, 9:32AM CDT
I've been getting so much hate mail and nasty tweets lately, I thought it would be fun to throw them all into a single column for funny Friday read. There's probably something deeper to be said about market psychology and what an uptick in hate mail... (full story)
(0)
(0)Arena Pharmaceuticals (ARNA) Stock Research Links
Scroll down for more posts ▼